Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Roche and Blueprint pursue immunotherapy
by Lisa M. Jarvis
March 21, 2016
| A version of this story appeared in
Volume 94, Issue 12
Roche will pay Blueprint Medicines $45 million up front as part of a broad pact to develop small-molecule cancer immunotherapies. Roche has the option to license up to five small molecules targeting immunokinases, proteins that play a role in regulating immune cells’ response. Blueprint is tasked with early development of the drug candidates, and Roche can buy into each program after Phase I data are available. Blueprint could secure close to $1 billion more in option and milestone fees if Roche licenses all five programs.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X